This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2001 Aug;70(2):103-14.

doi: 10.1067/mcp.2001.116891.

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus

G T Tucker¹, J B Houston, S M Huang

Affiliations

PMID: 11503003
DOI: 10.1067/mcp.2001.116891

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus

G T Tucker et al. Clin Pharmacol Ther. 2001 Aug.

. 2001 Aug;70(2):103-14.

doi: 10.1067/mcp.2001.116891.

Authors

G T Tucker¹, J B Houston, S M Huang

Affiliation

¹ Molecular Pharmacology and Pharmacogenetics, Division of Clinical Sciences, University of Sheffield, The Royal Hallamshire Hospital, UK.

PMID: 11503003
DOI: 10.1067/mcp.2001.116891

No abstract available

PubMed Disclaimer

Similar articles

EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Eur J Pharm Sci. 2001 Jul;13(4):417-28. doi: 10.1016/s0928-0987(01)00148-8. Eur J Pharm Sci. 2001. PMID: 11480400 No abstract available.
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Pharm Res. 2001 Aug;18(8):1071-80. doi: 10.1023/a:1010994022294. Pharm Res. 2001. PMID: 11587475 Review. No abstract available.
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Br J Clin Pharmacol. 2001 Jul;52(1):107-17. doi: 10.1046/j.0306-5251.2001.temp.1441.x. Br J Clin Pharmacol. 2001. PMID: 11453898 Free PMC article. Review. No abstract available.
Pharmacokinetic drug interactions in liver disease: An update.
Palatini P, De Martin S. Palatini P, et al. World J Gastroenterol. 2016 Jan 21;22(3):1260-78. doi: 10.3748/wjg.v22.i3.1260. World J Gastroenterol. 2016. PMID: 26811663 Free PMC article. Review.
Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats.
Zhang YH, Zhang YJ, Guo YL, Li WJ, Yu C. Zhang YH, et al. J Pharm Pharmacol. 2013 Jan;65(1):149-55. doi: 10.1111/j.2042-7158.2012.01579.x. Epub 2012 Aug 29. J Pharm Pharmacol. 2013. PMID: 23215698

See all similar articles

Cited by

Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.
Kharasch ED, Whittington D, Ensign D, Hoffer C, Bedynek PS, Campbell S, Stubbert K, Crafford A, London A, Kim T. Kharasch ED, et al. Clin Pharmacol Ther. 2012 Apr;91(4):673-84. doi: 10.1038/clpt.2011.276. Epub 2012 Mar 7. Clin Pharmacol Ther. 2012. PMID: 22398970 Free PMC article.
Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).
Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. Kharasch ED, et al. Anesthesiology. 2012 Feb;116(2):432-47. doi: 10.1097/ALN.0b013e3182423478. Anesthesiology. 2012. PMID: 22273859 Free PMC article.
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards.
Tiryannik I, Heikkinen AT, Gardner I, Onasanwo A, Jamei M, Polasek TM, Rostami-Hodjegan A. Tiryannik I, et al. Clin Pharmacokinet. 2025 Jan;64(1):155-170. doi: 10.1007/s40262-024-01457-1. Epub 2024 Dec 10. Clin Pharmacokinet. 2025. PMID: 39656410 Free PMC article.
Identification of the cytochrome P450 enzymes involved in the oxidative metabolism of trantinterol using ultra high-performance liquid chromatography coupled with tandem mass spectrometry.
Li K, Guo X, Qin F, Xiong Z, Zhao L, Yu J. Li K, et al. RSC Adv. 2018 Oct 10;8(60):34764-34772. doi: 10.1039/c8ra06219f. eCollection 2018 Oct 4. RSC Adv. 2018. PMID: 35548639 Free PMC article.
Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.
Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Khojasteh SC, et al. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16. doi: 10.1007/s13318-011-0024-2. Epub 2011 Feb 19. Eur J Drug Metab Pharmacokinet. 2011. PMID: 21336516 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information